Horizon Discovery Group PLC’s (HZD) Buy Rating Reaffirmed at Panmure Gordon
Horizon Discovery Group PLC (LON:HZD)‘s stock had its “buy” rating reiterated by analysts at Panmure Gordon in a research note issued on Monday. They presently have a GBX 205 ($2.67) target price on the stock. Panmure Gordon’s target price indicates a potential downside of 0.49% from the stock’s previous close.
A number of other brokerages have also recently commented on HZD. Beaufort Securities reaffirmed a “speculative buy” rating on shares of Horizon Discovery Group PLC in a report on Wednesday, January 25th. Numis Securities Ltd reissued a “buy” rating and set a GBX 262 ($3.41) price target on shares of Horizon Discovery Group PLC in a report on Thursday, March 2nd. Finally, N+1 Singer reissued a “buy” rating and set a GBX 194 ($2.52) price target on shares of Horizon Discovery Group PLC in a report on Tuesday, March 14th.
Shares of Horizon Discovery Group PLC (LON:HZD) traded up 4.37% during trading on Monday, hitting GBX 215.00. The stock had a trading volume of 185,561 shares. The firm’s market capitalization is GBX 202.36 million. Horizon Discovery Group PLC has a 1-year low of GBX 104.00 and a 1-year high of GBX 218.00. The stock’s 50-day moving average price is GBX 202.37 and its 200 day moving average price is GBX 166.07.
Horizon Discovery Group PLC Company Profile
Horizon Discovery Group PLC is a gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. The Company’s gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer.
Receive News & Ratings for Horizon Discovery Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Discovery Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.